Samsung BioLogics and F. Hoffmann-La Roche have entered into a long-term strategic manufacturing agreement under which Samsung will manufacture Roche’s commercial biologic medicines at its two manufacturing facilities in Incheon, South Korea. One of the facilities is currently under construction. Financial terms and products under the agreement were not disclosed.   “We are pleased to announce this strategic manufacturing relationship with Roche and look forward to delivering best-in...